AstraZeneca PLC $AZN Stock Position Decreased by Legacy Capital Wealth Partners LLC

Legacy Capital Wealth Partners LLC trimmed its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 10.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,444 shares of the company’s stock after selling 971 shares during the quarter. Legacy Capital Wealth Partners LLC’s holdings in AstraZeneca were worth $590,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its stake in AstraZeneca by 30.9% in the first quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock valued at $1,003,124,000 after acquiring an additional 3,224,251 shares during the last quarter. Valeo Financial Advisors LLC increased its stake in shares of AstraZeneca by 14,797.3% during the 2nd quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock worth $162,306,000 after purchasing an additional 2,307,047 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of AstraZeneca by 2,389.9% during the 2nd quarter. Acadian Asset Management LLC now owns 2,043,850 shares of the company’s stock valued at $142,798,000 after purchasing an additional 1,961,764 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of AstraZeneca by 406.9% in the 1st quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock valued at $148,517,000 after purchasing an additional 1,621,974 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in shares of AstraZeneca by 15.2% in the 2nd quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after purchasing an additional 1,605,133 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Down 0.8%

AstraZeneca stock opened at $92.60 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $94.01. The firm has a fifty day moving average price of $84.55 and a two-hundred day moving average price of $77.69. The firm has a market cap of $287.19 billion, a price-to-earnings ratio of 34.81, a P/E/G ratio of 1.52 and a beta of 0.34.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business had revenue of $15.19 billion for the quarter, compared to analyst estimates of $14.75 billion. During the same period in the previous year, the company posted $2.08 earnings per share. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. As a group, analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Jefferies Financial Group assumed coverage on AstraZeneca in a research note on Monday, October 27th. They set a “buy” rating for the company. Finally, Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.